Biocon Limited (BIOCON) AI Stock Analysis

• Market Cap: ₹478.53B
• Dividend Yield: 0.14%
• Average Volume (3M): 143.80K
• Price to Earnings (P/E): 111.9
• Beta (1Y): 1.30
• Revenue Growth: 6.80%
• EPS Growth: -75.66%
• Country: IN
• Employees: 16,315
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 0.26
• Shares Outstanding: 1,336,963,600
• 10 Day Avg. Volume: 71,148
• 30 Day Avg. Volume: 143,801
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹371.75
• Price Target Upside: 5.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: ₹377.00 ▲(6.77% Upside)

Biocon Limited's overall stock score is primarily influenced by its strong financial performance, which is the most significant factor. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which negatively impacts the score. The absence of earnings call data and notable corporate events means these factors do not influence the score.

Biocon Limited Business Overview & Revenue Model

Company Description

Biocon Limited is a leading global biopharmaceutical company headquartered in India, engaged in the development, manufacturing, and commercialization of innovative and affordable biosimilars, novel biologics, and complex generics. It operates in key sectors such as biopharmaceuticals, branded formulations, and research services. The company's core products include biosimilars for diabetes, oncology, and immunology, along with small molecules and branded generic formulations.

How the Company Makes Money

Biocon Limited generates revenue through multiple streams, primarily from the sales of its biosimilars, small molecules, and branded formulations. The company markets its products globally, with a strong presence in emerging markets and growing penetration in regulated markets such as the United States and Europe. Revenue is augmented by strategic partnerships and collaborations with large pharmaceutical companies for co-development and commercialization of its products. Biocon also earns income through its research services arm, Syngene International, which provides contract research and manufacturing services to global clients, thereby diversifying its income sources.

Biocon Limited Financial Statement Overview

Summary

Biocon Limited exhibits strong financial health with consistent revenue growth and profitability. The company's balance sheet is robust, with a solid equity base and manageable leverage. Cash flow generation is positive, supporting its operational needs. While there are minimal risks associated with rising debt levels, the overall financial outlook remains positive.

Income Statement

Biocon Limited has demonstrated strong revenue growth, with an increase in total revenue from 2024 to 2025. The gross profit margin is robust, reflecting efficient cost management, and the net profit margin is solid, indicating profitability. However, the EBIT margin has decreased compared to the previous year, suggesting potential operational challenges.

Balance Sheet

The company maintains a healthy equity ratio, signifying a strong capital structure with substantial stockholders' equity. The debt-to-equity ratio is reasonable, indicating balanced leverage, but the increase in total debt could pose future risks. The return on equity remains strong, reflecting effective use of equity capital.

Cash Flow

Biocon's operating cash flow has increased, underscoring improved cash generation from operations. The free cash flow is positive, indicating the company can fund its operations and investments, although the growth rate has slowed. The operating cash flow to net income ratio is favorable, showcasing efficient cash conversion.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	152.50B	150.52B	147.56B	111.74B	80.25B	62.12B
Gross Profit	89.24B	98.55B	91.73B	75.11B	53.01B	41.57B
EBITDA	32.70B	44.71B	41.53B	25.96B	20.72B	18.32B
Net Income	10.13B	10.13B	10.22B	4.63B	6.48B	7.48B
Balance Sheet
Total Assets	587.97B	587.97B	560.71B	520.43B	203.94B	144.44B
Cash, Cash Equivalents and Short-Term Investments	50.23B	50.23B	31.12B	38.59B	19.99B	10.54B
Total Debt	183.62B	183.62B	162.77B	180.19B	51.47B	27.15B
Total Liabilities	310.85B	310.85B	307.96B	295.54B	109.24B	70.61B
Stockholders Equity	216.44B	216.44B	197.84B	178.67B	84.33B	67.06B
Cash Flow
Free Cash Flow	0.00	17.18B	10.22B	1.26B	-7.48B	-5.53B
Operating Cash Flow	0.00	40.61B	29.54B	18.52B	11.77B	12.83B
Investing Cash Flow	0.00	-2.34B	-10.04B	-142.82B	-16.99B	-15.59B
Financing Cash Flow	0.00	-18.54B	-23.33B	130.49B	2.42B	3.88B

Biocon Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 353.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOCON, the sentiment is Negative. The current price of 353.1 is below the 20-day moving average (MA) of 364.39, below the 50-day MA of 369.96, and above the 200-day MA of 351.91, indicating a neutral trend. The MACD of -4.94 indicates Positive momentum. The RSI at 39.80 is Neutral, neither overbought nor oversold. The STOCH value of 36.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOCON.

Biocon Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYNGENE	68 Neutral	₹261.37B	51.33		0.20%	7.41%	2.88%
BLUEJET	68 Neutral	₹122.70B	34.21		0.14%	75.82%	127.85%
CONCORDBIO	67 Neutral	₹178.37B	50.09		0.51%	14.49%	13.70%
JUBLINGREA	63 Neutral	₹116.28B	41.50		0.69%	2.60%	60.61%
BIOCON	61 Neutral	₹478.53B	111.88		0.14%	6.80%	-75.66%
PPLPHARMA	60 Neutral	₹251.56B	255.85		0.08%	9.08%	249.08%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%

Biocon Limited Corporate Events

Biocon Limited Announces Q1 FY26 Earnings Call

Biocon Limited has announced its Q1 FY26 earnings call, scheduled for August 8, 2025, as part of its compliance with SEBI Listing Regulations. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

Biocon Releases QIP Fund Utilization Report for June 2025 Quarter

Biocon Limited has released its Monitoring Agency Report for the quarter ending June 30, 2025, detailing the utilization of funds raised through Qualified Institutions Placement (QIP). The report, issued by India Ratings and Research Private Limited, was reviewed by Biocon’s Audit Committee and Board of Directors. This disclosure is in compliance with the Securities and Exchange Board of India’s regulations, ensuring transparency in financial operations and maintaining investor confidence.

Biocon Biologics Secures FDA Approval for Interchangeable Insulin Aspart

Biocon Biologics Ltd, a subsidiary of Biocon Limited, has received FDA approval for Kirsty™, the first and only interchangeable rapid-acting Insulin Aspart in the United States. This approval marks a significant expansion of Biocon Biologics’ diabetes portfolio, complementing its existing product, Semglee®. The introduction of Kirsty™ aims to enhance accessibility and affordability of insulin, offering more treatment options for diabetes patients. With diabetes affecting 38.4 million people in the U.S., this approval positions Biocon Biologics as a key player in addressing unmet needs in diabetes care, reinforcing its commitment to scientific excellence and patient-centric innovation.

Biocon Biologics Achieves Insulin Supply Milestone in Malaysia

Biocon Biologics, a subsidiary of Biocon Limited, has achieved a significant milestone by supplying over 100 million cartridges of recombinant human insulin to Malaysia’s Ministry of Health, serving more than 345,000 patients since 2016. This accomplishment highlights Biocon’s commitment to improving diabetes care and ensuring affordable insulin access in Malaysia, supported by a successful public-private partnership with the Malaysian government and Duopharma Biotech Berhad. The collaboration has strengthened the local biotech ecosystem, advanced insulin self-sufficiency, and reinforced Biocon’s position as a leading player in the global insulin market.